Evidence map›Paper›PMID 26480818›Full record

ArticleBMC cancer2015

The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.

Emelie Englund, Bart Reitsma, Ben C King, Astrid Escudero-Esparza, Sioned Owen, Akira Orimo, Marcin Okroj, Lola Anagnostaki, Wen G Jiang, Karin Jirström and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Emelie EnglundDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. emelie.englund@med.lu.se.
Bart ReitsmaDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. bart.reitsma@med.lu.se.
Ben C KingDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. ben.king@med.lu.se.
Astrid Escudero-EsparzaDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. astrid.escudero_esparza@med.lu.se.
Sioned OwenCardiff's China Medical Research Collaborative (CCMRC), Cardiff University School of Medicine, Cardiff University, Cardiff, UK. owenS15@cardiff.ac.uk.
Akira OrimoDepartment of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan. aorimo@juntendo.ac.jp.
Marcin OkrojDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. marcin.okroj@med.lu.se.
Lola AnagnostakiDepartment of Clinical Pathology, Skåne University Hospital, Malmö, Sweden. lola.anagnostaki@skane.se.
Wen G JiangCardiff's China Medical Research Collaborative (CCMRC), Cardiff University School of Medicine, Cardiff University, Cardiff, UK. JiangW@cardiff.ac.uk.
Karin JirströmDepartment of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. karin.jirstrom@med.lu.se.
Anna M BlomDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Inga Maria Nilssons gata 53, 20502, Malmö, Sweden. anna.blom@med.lu.se.
Lund University · SEJuntendo University · JPSkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe human Sushi Domain-Containing Protein 4 (SUSD4) was recently shown to function as a novel inhibitor of the complement system, but its role in tumor progression is unknown.

methodsUsing immunohistochemistry and quantitative PCR, we investigated SUSD4 expression in breast cancer tissue samples from two cohorts. The effect of SUSD4 expression on cell migration and invasion was studied in vitro using two human breast cancer cell lines overexpressing SUSD4.

resultsTissue stainings revealed that both tumor cells and tumor-infiltrating cells expressed SUSD4. The highest SUSD4 expression was detected in differentiated tumors with decreased rate of metastasis, and SUSD4 expression was associated with improved survival of the patients. Moreover, forced SUSD4 expression in human breast cancer cells attenuated their migratory and invasive traits in culture. SUSD4 expression also inhibited colony formation of human breast cancer cells cultured on carcinoma-associated fibroblasts. Furthermore, large numbers of SUSD4-expressing T cells in the tumor stroma associated with better overall survival of the breast cancer patients.

conclusionOur findings indicate that SUSD4 expression in both breast cancer cells and T cells infiltrating the tumor-associated stroma is useful to predict better prognosis of breast cancer patients.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBreast NeoplasmsCell Line, TumorComplement Inactivator ProteinsFemaleHumansImmunohistochemistryMembrane ProteinsMicroscopy, FluorescenceMiddle AgedPolymerase Chain ReactionPrognosisRNA, NeoplasmComplement Inactivator ProteinsMembrane ProteinsRNA, NeoplasmSUSD4 protein, human

Identifiers

PMID26480818
PMCPMC4615997
OpenAlexW2102201312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.